MedPath
HSA Approval

MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml

SIN10690P

MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml

MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml

January 20, 1999

MEDOCHEMIE SINGAPORE PTE. LTD.

MEDOCHEMIE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMEDOCHEMIE SINGAPORE PTE. LTD.
Licence HolderMEDOCHEMIE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

POWDER, FOR SUSPENSION

ORAL

Medical Information

J01CR02

amoxicillin and beta-lactamase inhibitor

Manufacturer Information

MEDOCHEMIE SINGAPORE PTE. LTD.

Medochemie Ltd – Factory B

Active Ingredients

AMOXYCILLIN TRIHYDRATE EQV AMOXYCILLIN

125 mg/5 ml

Amoxicillin

CLAVULANATE POTASSIUM EQV CLAVULANIC ACID

31.25 mg/5 ml

Clavulanic acid

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MOXICLAV DRY POWDER FOR ORAL SUSPENSION 156.25 mg/5 ml - HSA Approval | MedPath